Measurement of human growth hormone (hGH; somatotropin) concentrations in serum after provocativetests is crucial for diagnosing deficiencies in production of this hormone. Serum hGH can be measured by various immunoassays, isotopic and nonisotopic, with monoclonal or polyclonal antibodies: a cutoff value of 10 /L after provocative testing is usually used to distinguish normal from hGH-deficient children. Previous studies demonstrated discrepancies in hGH measurement by different radioisotopic immunoassays. Here we present a study of hGH quantification involving six commercial kits, radioisotopic and nonisotopic, based on competitive or sandwich methodology and monoclonal or polyclonal antibodies.
Measurement of somatotropin
(human growth hormone; hGH) concentrations in serum after a provocative test is crucial for diagnosing deficiencies and (or) disturbances in the production of this hormone (1).1 hGH in serum can be measured by various methods, isotopic or nonisotopic. Radioimmunoassay (RLA), immunoradiometric (IRMA), and immunoenzymometric assay (IRMA) are commercially available for routine laboratory use. RIAs often involve use of polyclonal antibodies, whereas IRMASand IEMASare based on monoclonal ones (2) . Some studies have reported disagreement among different methods (2) (3) (4) (5) (6) , ascribing the origin of discordant results to differences among antibodies ( For quality control for all the kits, we used Lyphocheck Immunoassay Control Serum (BioRad, Anaheim, CA).SThe intra-and interassay CVs for all the kits used were <10%.
Patients' Sera
The analyzed 96 sera obtained from provocative tests (clonidine 150 pg/m2 of body surface orally) ( 2, 14, 15) .
Nomsotopic assays for hGH have been proposed (6, 11) , involving sandwich methodology and monoclonal antibodies. Discrepancies have been confirmed by using these novel assays, which have a specifictracer activity different from that of isotopic ones (6). In previous studies, however, discordant hGH results observed by using various, but exclusively radioisotopic, commercial kits have been studied and sometimes explained only by using comparison tests (3) (4) (5) (6) or by performing dilution tests with use of recombinant hGH (2). We performed parallelism tests with different materials (international standard, pure hGH, and serum with high hGH content) to ensure that the kits, although presenting discrepant absolute values, give the same performance for three diluted matrices. Indeed, each kit presented a peculiar but constant behavior in these experiments. Thus, matrix differences did not affect or only slightly affected the kits' performances.
Conversely, the relevance of heterogeneity of the antibodies must be emphasized. The commercial use of monoclonal antibodies against different hGH epitopes could be affected by stochastic and heteroclitic production (7) and by various forms of hormone (2, 8) . The mix of carefully selected monoclonal antibodies could provide an elegant solution to the problem (11). The difficulties induced by heterogeneity could reduce the clinical impact of monoclonal IRMAS, because the increased specificity is accompanied by other interferences condusive to misclassifications and confusions. This could have potentially serious consequencesfor diagnosis, as was described for two of the 16 children examined. At present, it is difficult to recommend a method of choice for measuring the "real" hGH, although the Hybritech IRMA kit seems to be influenced the least by extraneous variables (2) and the RIA RSL seems to be the nearest to bioassayable hGH (16).
It is important, however, that cutoff values adopted by the laboratory be well grounded in experience and clinically approved. We established the validity of a 10 /1gfL cutoff value for our routinely used kit (RSL) by a computer-assisted study of 300 tests (arginine or clothdine provocative tests in children). In addition, the cutoff values and reference values of each commercially available kit must be clearly defined by the manufacturers. For example, the two curves with discrepant absolute hGH values could be brought into conformity by adopting a discriminant value of 7 .LgfL.However, all of the manufacturers indicated 10 gfL as the decision value for hGH in provocative tests.
Another proposal could be that the international hGH standards be unified, thereby simplifying the manufacturers' production. In addition, standardization of monoclonal antibodies, with specificity studies and performance descriptions, can be made and acknowledged.
